Management Team

Noa Shelach Ph.D, MBA

Chief Executive Officer

Dr. Noa Shelach is a senior biopharmaceutical executive with over 20 years of experience in drug development as well in VC investments. Prior to Lutris-Pharma, Dr. Shelach held CEO positions in leading private and public biopharmaceutical companies: NextGen Healthcare, Integra Holdings, Campus Bio (Held by: Clal Biotechnology Industries TASE: CBI) and Braintact. In all her roles Dr. Shelach managed all aspects of drug development: technology assessment, pre-clinical and clinical stage development and commercialization. Prior to that, Dr. Shelach held VP R&D position in Keryx Biopharmaceuticals (NASDAQ: KRX), managing the entire company portfolio. Dr Shelach serves as a director member in several biopharmaceutical companies and is a member of NGT incubator investment committee.

Ben Corn M.D

Chief Medical Officer

Ben Corn is a graduate of the accelerated BA-MD program in medical science of Boston University, where he graduated with honors. He trained at the University of Pennsylvania where he served as Chief Resident in Radiation Oncology. He stayed on at Penn as an Assistant Professor, then became Associate Professor at Fox Chase Cancer Center before being promoted to Full Professor at Jefferson Medical College in Philadelphia. He immigrated to Israel in 1997 and served as President of Signal Site before becoming CEO of Keryx Biopharmaceuticals. He has functioned in advisory roles for multiple Israeli biotech and device companies including Novotech, Galmed and Izun. He has published over 250 articles in the peer-reviewed literature. Currently, he is Chief Medical Officer of Lutris as well as Professor and Deputy Director of the Shaare Zedek Cancer Center in Jerusalem.

John Paul Waymack M.D, Sc.D

Director, Regulatory Affairs

Dr. John Paul Waymack was previously an associate professor of surgery at the New Jersey School of Medicine and Dentistry, and an FDA medical officer.  After leaving the FDA, he worked as a consultant to multiple pharmaceutical and biotechnology corporations.  More recently, he was the founder and is the chairman of the Board of Directors of Kitov Pharmaceuticals (NASDAQ: KTOV). Dr. Waymack currently serves on a number of boards for multiple biotechnology corporations.

Colleen Johnson M.S, DABT

Director, Pre-Clinical Development

As a board certified toxicologist, Ms. Johnson has been assisting pharmaceutical companies with all phases of nonclinical development for more than 20 years.  Activities include representing clients at FDA, negotiating nonclinical testing strategies, preparing INDs, NDAs, briefing documents, and monitoring studies.  Prior to that she worked in agricultural and industrial chemical product registrations with EPA and litigation support work.

Laura Millichamp Ph.D

Director, Chemistry Manufacturing Control

Dr Laura Millichamp qualified as a Pharmacist, before completing a PhD in the field of topical products. She was a Pharmaceutical Assessor at the MHRA for over 7 years, where she assessed Marketing Authorization Applications and Scientific Advice requests submitted through National and European procedures. Laura then moved into Consulting supporting companies at all stages of product development with strategic and technical advice relating to activities including IND/IMPD data generation and authoring, early access initiatives (PRIME/ODD applications), Scientific Advice procedures, Marketing Authorization Applications and Lifecycle Maintenance.